ArticlePloS one2017
Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Epidemiological trends and novel prognostic evaluation approaches of patients with stage II-IV colorectal neuroendocrine neoplasms: A population-based study with external validation.Frontiers in endocrinology · 2023Trial
- Intra-Individual variation in radiation dose of pediatric head CT: implications for dose optimization.Neuroradiology · 2026Observational
- Recent updates on the endoscopic treatment of rectal neuroendocrine tumor.Intestinal research · 2026Review
- LncRNA PCAT6 promotes progression and metastasis of colonic neuroendocrine carcinomaWorld journal of gastrointestinal oncology · 2025Article
- Case study of a neuroendocrine tumor of uncertain origin: single-cell transcriptomics unravels potential primary location.Journal of cancer research and clinical oncology · 2024Article
- Treatment indicators and prognostic factors in colorectal neuroendocrine neoplasms and adenocarcinoma with neuroendocrine differentiation: a single center retrospective study.International journal of colorectal disease · 2024Article
- Does gamma-glutamyltransferase correlate with liver tumor burden in neuroendocrine tumors?Endocrine · 2024Article
- Predictive and prognostic nomogram models for liver metastasis in colorectal neuroendocrine neoplasms: a large population study.Frontiers in endocrinology · 2024Article
- Multicenter Analysis of Presacral Neuroendocrine Neoplasms-Clinicopathological Characterization and Treatment Outcomes of a Rare Disease.Frontiers in endocrinology · 2021Article
- Large cell neuroendocrine carcinoma in the unusual location of the descending colon.Radiology case reports · 2020Article
- The Neuroendocrine Neoplasms of the Digestive Tract: Diagnosis, Treatment and Nutrition.Nutrients · 2020Review
- Colorectal neuroendocrine tumors: A case series.International journal of surgery case reports · 2020Article
- Article
- Analysis of 72 patients with colorectal high-grade neuroendocrine neoplasms from three Chinese hospitals.World journal of gastroenterology · 2019Observational
- Endoscopic features and associated histology of an basaloid squamous cell carcinoma of the esophagus at the very early stage.BMC cancer · 2019Article
- Management of Gastrointestinal Neuroendocrine Tumors.Clinical medicine insights. Endocrinology and diabetes · 2019Review
- Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.Medical sciences (Basel, Switzerland) · 2018Review
- Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors.International journal of endocrinology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromogranin A (CgA) is a well-established marker for diagnosis and follow up of patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN). Recently, it has been shown that plasma levels of CgA correlate with tumor load and predict survival of patients with NEN of the small bowel. It is assumed that this is as well valid for NEN of the colon and rectum, however, this is not supported by data. To evaluate this assumption, we analyzed 62 patients with NEN of the colon and rectum listed in the Marburg GEP-NEN registry for clinicopathological characteristics, expression and plasma levels of CgA. The present study demonstrates that immunohistochemical CgA and synaptophysin are good markers for histological diagnosis in patients with NEN of the colon and rectum. However, plasma CgA is a poor marker to follow-up these patients because only a minority exhibited increased levels which did not increase significantly during tumor progression. In contrast to NEN of the small bowel, there is no correlation of CgA plasma levels with tumor burden or survival. Patients with NEN of the colon and rectum displayed a relatively good prognosis resulting in a median survival of 8.5 years. However, a subset of patients affected by G3 neoplasms, exhibited a poorer prognosis with a median survival of 2.5 years. Taken together, CgA is a valuable marker for immunohistochemical diagnosis, but CgA plasma concentration is not suitable to mirror tumor burden or prognosis in patients with NEN of the colon and rectum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.